GlassScriptPhysician profile
Kellee R Swider
NPI 1265822878
$9,562.58
in general payments reported to CMS, 2019-2025
50 companies · $18.50 in 2025
The $18.50 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,009 · 2022: $4,329 · 2023: $4,190 · 2024: $16.08 · 2025: $18.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725 · Long Term Medical Supply Or Device Loan: $299 · Consulting Fee: $105 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.98 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Consulting Fee | $105.00 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,131.59 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $590.67 | 2022-2023 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $571.44 | 2021-2023 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $516.66 | 2021-2023 | Darzalex, Tecvayli, Imbruvica |
| Incyte Corporation | $512.65 | 2021-2023 | Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $415.08 | 2021-2023 | Keytruda, Lynparza |
| Pfizer INC. | $410.67 | 2021-2023 | |
| Genentech USA, INC. | $398.99 | 2022-2023 | Polivy, Lunsumio, Venclexta |
| Genzyme Corporation | $381.33 | 2021-2023 | |
| Gilead Sciences, INC. | $362.10 | 2022-2023 | Trodelvy |
| Beigene USA, INC. | $359.80 | 2021-2023 | Brukinsa |
| Eisai INC. | $286.88 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.93 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $268.76 | 2021-2023 | Imbruvica |
| Celgene Corporation | $259.79 | 2021-2023 | Pomalyst, Reblozyl |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $214.53 | 2021-2023 | |
| Glaxosmithkline, LLC. | $207.60 | 2021-2023 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $206.32 | 2022-2023 | Enhertu, Injectafer |
| Amgen INC. | $190.34 | 2021-2023 | Lumakras |
| Lilly USA, LLC | $165.24 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $160.80 | 2021-2023 | Alunbrig |
| Stemline Therapeutics INC. | $157.73 | 2023 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $130.22 | 2021-2023 | Libtayo |
| Sobi, INC | $126.90 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $104.49 | 2021-2023 | Onivyde, Somatuline Depot, Tazverik |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Cti Biopharma Corp. | $97.67 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $92.19 | 2022-2023 | Ultomiris |
| Emd Serono, INC. | $88.69 | 2021-2023 | Bavencio |
| Astellas Pharma US INC | $87.34 | 2022-2023 | Padcev |
| Myovant Sciences INC. | $81.70 | 2022 | |
| G1 Therapeutics, INC. | $79.45 | 2022-2023 | Cosela |
| Exelixis INC. | $58.87 | 2021-2023 | Cabometyx |
| Mylan Institutional INC. | $53.98 | 2022-2023 | Ogivri, Fulphila |
| Seagen INC. | $52.36 | 2021-2023 | Tukysa, Adcetris |
| Puma Biotechnology, INC. | $46.70 | 2021-2022 | |
| Morphosys, US INC. | $39.93 | 2021-2022 | |
| Blueprint Medicines Corporation | $37.98 | 2022 | |
| Mirati Therapeutics, INC. | $36.74 | 2023 | Krazati |
| Taiho Oncology, INC. | $36.11 | 2022-2023 | |
| Kite Pharma, INC. | $28.47 | 2022-2023 | |
| Abbvie INC. | $23.33 | 2023 | |
| Biogen, INC. | $21.05 | 2021 | |
| Adaptive Biotechnologies Corporation | $15.70 | 2023 | Clonoseq |
| Recordati_rare_diseases_inc. | $15.31 | 2023 | Panhematin |
| Aveo Pharmaceuticals, INC. | $14.35 | 2022 | |
| Karyopharm Therapeutics INC. | $14.16 | 2023 | Xpovio |
| Dova Pharmaceuticals | $13.97 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.49 | 2022 | |
| Kyowa Kirin, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellee Swider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.